Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript
Operator: Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call.
Revance Therapeutics Inc. (RVNC)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Palo Alto Investors William Leland Edwards | 5,237,284 | $46,035,726 | +1% | 4.14% |
| 2. | 38,122,000 | $28,966,901 | 0.02% | ||
| 3. | Polar Capital Brian Ashford-Russell And Tim Woolley | 3,169,239 | $27,857,611 | -24% | 0.17% |
| 4. | 31,929,000 | $24,372,469 | 0.53% | ||
| 5. | 20,000,000 | $14,429,400 | -5% | 0.58% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.98 | 30,000 | Officer, Director | 1,015,468 | 2024-03-06 | Filing | |
| $15.74 | 6,400 | Director | 26,913 | 2021-12-13 | Filing | |
| $14.43 | 30,000 | Officer, Director | 95,463 | 2021-12-03 | Filing | |
| $12.90 | 40,000 | Officer, Director | 110,913 | 2021-11-29 | Filing | |
| $31.20 | 900 | Director | 6,150 | 2018-03-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.80 | 2,392 | Officer | 114,864 | 2024-04-16 | Filing | |
| $5.04 | 9,211 | Officer | 167,550 | 2024-03-18 | Filing | |
| $5.04 | 8,125 | Officer | 137,815 | 2024-03-18 | Filing | |
| $5.04 | 9,361 | Officer | 192,666 | 2024-03-18 | Filing | |
| $17.06 | 11,000 | Officer | 44,066 | 2023-09-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,939,076 | $104,944,478 | 0.01% | |
| 2. | 7,453,371 | $65,515,131 | 0% | |
| 3. | 5,069,625 | $44,562,004 | 0% | |
| 4. | 4,749,539 | $41,748,450 | 0.01% | |
| 5. | 4,643,419 | $40,815,652 | 0% |
News See All
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Call Transcript
Operator: Welcome to the Revance Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
13 Stocks to Buy with Exponential Growth
Optimism was prevailing in the US stock market on October 11 as investors were hopeful that the Federal Reserve won’t take a hawkish stance for the rest of the year amid rising bond yields that are ...
Revance Therapeutics (RVNC) Shares Declined on Profit-Taking
Baron Funds, an investment management company, released its “Baron Discovery Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here.
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q2 2023 Earnings Call Transcript
Operator: Welcome to the Revance Therapeutics Second Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
10 Oversold Biotech Stocks to Buy
In this article, we will take a look at the 10 oversold biotech stocks to buy.
10 Best Revenue Growth Stocks to Buy
In this piece, we will take a look at the ten best revenue growth stocks to buy.
Here's Why Revance Therapeutics (RVNC) Outperformed in Q1
Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2023 Earnings Call Transcript
Operator: Welcome to the Revance Therapeutics First Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2022 Earnings Call Transcript
Operator: Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.